Showing results (181-190 of 204) with videos related to

Sort By:
Pageof 21
British Journal of Cancer|March 20, 2003
IDN 5390: an oral taxane candidate for protracted treatment schedulesG Pratesi, D Laccabue, C Lanzi, et al.
Biochimica Et Biophysica Acta|December 27, 1995
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lungG Giaccone, J van Ark-Otte, G Scagliotti, et al.
Apoptosis : an International Journal on Programmed Cell Death|January 1, 1997
Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell linesP Perego, S C Righetti, R Supino, et al.
Biochemical Pharmacology|May 30, 2001
A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogueM Bigioni, C Salvatore, A Bullo, et al.
Biochemical Pharmacology|January 24, 1997
Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenedionesP de Isabella, M Palumbo, C Sissi, et al.
Journal of Medicinal Chemistry|September 10, 1999
8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluationB Stefańska, M Dzieduszycka, M M Bontemps-Gracz, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 6, 2000
Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcomaT Mancuso, A Mezzelani, C Riva, et al.
Journal of Cell Science|July 13, 2000
Membrane gamma-glutamyl transpeptidase activity of melanoma cells: effects on cellular H(2)O(2) production, cell surface protein thiol oxidation and NF-kappa B activation statusE Maellaro, S Dominici, B Del Bello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatinC Manzotti, G Pratesi, E Menta, et al.
Biochemical Pharmacology|August 27, 1998
Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistanceC Lanzi, P Perego, R Supino, et al.
Pageof 21